Welcome to our dedicated page for Cadrenal Therape SEC filings (Ticker: CVKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including Current Reports on Form 8-K, proxy materials, and other documents filed with the Securities and Exchange Commission. As an emerging growth biopharmaceutical company focused on anticoagulant therapies, Cadrenal uses these filings to report material events, governance matters, and financing activities that shape its clinical and corporate trajectory.
Investors researching CVKD can use this page to review Form 8-K filings that describe offerings of common stock and warrants, at-the-market equity programs, and other capital-raising transactions. Additional 8-K reports furnish quarterly financial results, including research and development spending and general and administrative expenses, which help illustrate how resources are being allocated to programs such as tecarfarin, frunexian, and VLX-1005.
The company’s definitive proxy statement on Schedule 14A offers detail on board composition, annual meeting proposals, and governance practices. Over time, annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide broader context on risk factors, clinical development plans, and the status of regulatory designations for Cadrenal’s anticoagulation pipeline.
Stock Titan enhances this document set with AI-powered summaries that explain the key points of lengthy filings in plain language. Users can quickly understand the implications of a new financing, changes in capital structure, or updates to clinical strategy without reading every page. The platform also surfaces insider and beneficial ownership information when disclosed, helping users see how management and major holders are aligned with the company’s progress. With real-time updates from EDGAR and AI-generated insights, this page is designed to make Cadrenal’s regulatory record more accessible and easier to interpret.
Cadrenal Therapeutics (CVKD) reported unaudited results for the quarter ended June 30, 2025 showing a quarterly net loss of $3.67 million and a six‑month net loss of $7.51 million. Cash and cash equivalents were $5.57 million at June 30, 2025 and approximately $5.0 million as of August 6, 2025, which the company states is expected to fund operations for at least the next twelve months from the filing date. Working capital was about $4.3 million and the accumulated deficit stood at $33.2 million. As of August 11, 2025, there were 2,046,854 shares outstanding.
Operating expenses increased year‑over‑year: six‑month general and administrative expenses rose to $4.91 million (110% increase) and research and development expenses rose to $2.75 million (46% increase) driven by CMC, personnel and clinical preparation costs. Financing activity included $3.35 million gross ATM proceeds in H1 2025 and an additional ~$516,000 gross via ATM in July 2025. Tecarfarin holds orphan and fast‑track designations for specified indications and the company announced clinical trial initiation plans for ESKD patients transitioning to dialysis on August 5, 2025.